EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 4.54

Change

-0.08 (-1.73)%

Market Cap

N/A

Volume

0.61M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.82 (-1.22%)

USD 66.32B
HLN Haleon plc

-0.03 (-0.29%)

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.22 (+1.50%)

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.39B
ELAN Elanco Animal Health

+0.04 (+0.47%)

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.23 (-3.13%)

USD 3.25B
BHC Bausch Health Companies Inc

-0.38 (-7.45%)

USD 1.60B
CPHI China Pharma Holdings Inc

N/A

USD 4.61M
YCBD cbdMD Inc

N/A

USD 1.44M
EVT Eaton Vance Tax Advantaged Div..

-0.58 (-2.72%)

N/A

ETFs Containing EBS

PIEQ Principal International E.. 3.81 % 0.00 %

-0.40 (-1.56%)

USD 0.72B
FPXE First Trust IPOX Europe E.. 2.71 % 0.00 %

-0.28 (-1.56%)

USD 3.72M
C005:XETRA Amundi Index Solutions - .. 2.69 % 0.00 %

N/A

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 2.10 % 0.00 %

N/A

USD 0.17B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

N/A

N/A
LGGE:XETRA L&G Quality Equity Divide.. 1.23 % 0.00 %

N/A

USD 0.03B
EL43:XETRA Deka MSCI Europe MC UCITS.. 1.12 % 0.00 %

N/A

USD 0.02B
EUMD:LSE iShares MSCI Europe Mid C.. 1.12 % 0.00 %

N/A

USD 0.49B
FDT First Trust Developed Mar.. 0.00 % 0.80 %

-0.04 (-1.56%)

USD 0.43B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
IS3H:XETRA iShares MSCI EMU Mid Cap .. 0.00 % 0.00 %

N/A

N/A
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

N/A
FTEU:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.05B
FTGE:XETRA First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

N/A
IWSZ:SW iShares Edge MSCI World S.. 0.00 % 0.00 %

N/A

USD 0.28B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.51% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.51% 7% C- 2% F
Trailing 12 Months  
Capital Gain 110.19% 93% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.19% 93% A 98% N/A
Trailing 5 Years  
Capital Gain -93.18% 23% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.18% 23% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -4.44% 36% F 16% F
Dividend Return -4.44% 36% F 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 133.12% 21% F 6% D-
Risk Adjusted Return -3.33% 36% F 20% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector